CF Trust: U.K. health secretary backs NHS in Vertex stalemate

Secretary of State for Health and Social Care Matt Hancock told the Cystic Fibrosis Trust that he is not willing to let Orkambi ivacaftor/lumacaftor set a precedent that will “expose the NHS to accepting the price of new medicines set by pharmaceutical companies at face value,” the U.K.-based patient advocacy group said in a blog post Thursday.

The Cystic Fibrosis Trust wrote

Read the full 616 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE